Cargando…

Efficacy and Safety of Naloxegol in Patients with Chronic Non-Cancer Pain Who Experience Opioid-Induced Constipation: A Pooled Analysis of Two Global, Randomized Controlled Studies

OBJECTIVE: This study evaluates the onset, magnitude, and consistency of improvement of opioid-induced constipation (OIC) symptoms with naloxegol treatment. METHODS: This was a pooled analysis of two Phase 3, double-blind, randomized, placebo-controlled studies (KODIAC-04/05, NCT01309841/NCT01323790...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chey, William D, Brenner, Darren M, Cash, Brooks D, Hale, Martin, Adler, Jeremy, Jamindar, Mansi S, Rockett, Carol B, Almenoff, June S, Bortey, Enoch, Gudin, Jeffrey
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10473436/ https://www.ncbi.nlm.nih.gov/pubmed/37664485 http://dx.doi.org/10.2147/JPR.S417045

Ejemplares similares

Development of a new travellers’ diarrhoea clinical severity classification and its utility in confirming rifamycin-SV efficacy
por: DuPont, Herbert L, et al.
Publicado: (2023)

Clinical utility of naloxegol in the treatment of opioid-induced constipation
por: Bruner, Heather C, et al.
Publicado: (2015)

Impact of Treatment with Naloxegol for Opioid-Induced Constipation on Patients’ Health State Utility
por: Lawson, Richard, et al.
Publicado: (2016)

Effectiveness of naloxegol in patients with cancer pain suffering from opioid-induced constipation
por: Lemaire, Antoine, et al.
Publicado: (2021)

Evaluating the Safety and Efficacy of Naloxegol in Critically Ill Opioid-Induced Constipation Patients
por: Rizwan, M. Zeeshan, et al.
Publicado: (2023)

Naloxegol: First oral peripherally acting mu opioid receptor antagonists for opioid-induced constipation
por: Anantharamu, Tejus, et al.
Publicado: (2015)

Naloxegol in opioid-induced constipation: a new paradigm in the treatment of a common problem
por: Yoon, Stephanie C, et al.
Publicado: (2017)

Correction to: Effectiveness of naloxegol in patients with cancer pain suffering from opioid‑induced constipation
por: Lemaire, Antoine, et al.
Publicado: (2021)

Analysis of opioid-mediated analgesia in Phase III studies of methylnaltrexone for opioid-induced constipation in patients with chronic noncancer pain
por: Webster, Lynn R, et al.
Publicado: (2015)

A Randomized, Multicenter, Prospective, Crossover, Open-Label Study of Factors Associated With Patient Preferences for Naloxegol or PEG 3350 for Opioid-Induced Constipation
por: Brenner, Darren M., et al.
Publicado: (2019)

Pharmacologic Profile of Naloxegol, a Peripherally Acting µ-Opioid Receptor Antagonist, for the Treatment of Opioid-Induced Constipation
por: Floettmann, Eike, et al.
Publicado: (2017)

Population Exposure‐Response Modeling of Naloxegol in Patients With Noncancer‐Related Pain and Opioid‐Induced Constipation
por: Al‐Huniti, N, et al.
Publicado: (2016)

Population Exposure‐Response Modeling Supported Selection of Naloxegol Doses in Phase III Studies in Patients With Opioid‐Induced Constipation
por: Al‐Huniti, Nidal, et al.
Publicado: (2017)

Naloxegol to Prevent Constipation in ICU Adults Receiving Opioids: A Randomized Double-Blind Placebo-Controlled Pilot Trial
por: Duprey, Matthew S., et al.
Publicado: (2022)

Effect of Naloxegol on Opioid-Induced Esophageal Motility Disorder
por: Ulteig, Crista, et al.
Publicado: (2022)

A Prospective, Real-World, Multinational Study of Naloxegol for Patients with Cancer Pain Diagnosed with Opioid-Induced Constipation—The NACASY Study
por: Davies, Andrew, et al.
Publicado: (2022)

Clinical potential of naloxegol in the management of opioid-induced bowel dysfunction
por: Poulsen, Jakob Lykke, et al.
Publicado: (2014)

Efficacy of naloxegol on symptoms and quality of life related to opioid-induced constipation in patients with cancer: a 3-month follow-up analysis
por: Cobo Dols, Manuel, et al.
Publicado: (2021)

Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double‐blind, placebo‐controlled trials
por: Schoenfeld, P., et al.
Publicado: (2014)

Tegaserod for Irritable Bowel Syndrome With Constipation in Women Younger Than 65 Years Without Cardiovascular Disease: Pooled Analyses of 4 Controlled Trials
por: Shah, Eric D., et al.
Publicado: (2021)

Peripheral Opioid Receptor Antagonists for Opioid-Induced Constipation: A Primer on Pharmacokinetic Variabilities with a Focus on Drug Interactions
por: Gudin, Jeffrey, et al.
Publicado: (2020)

Efficacy and safety of linaclotide for opioid-induced constipation in patients with chronic noncancer pain syndromes from a phase 2 randomized study
por: Brenner, Darren M., et al.
Publicado: (2020)

Consensus Recommendations on Initiating Prescription Therapies for Opioid‐Induced Constipation
por: Argoff, Charles E., et al.
Publicado: (2015)

Naloxegol and Postoperative Urinary Retention: A Randomized Trial
por: Turan, Alparslan, et al.
Publicado: (2022)

Pitfalls of Physician-Directed Treatment of Helicobacter pylori: Results from Two Phase 3 Clinical Trials and Real-World Prescribing Data
por: Howden, Colin W., et al.
Publicado: (2021)

Emerging Pharmacologic Therapies for Constipation-predominant Irritable Bowel Syndrome and Chronic Constipation
por: Eswaran, Shanti, et al.
Publicado: (2014)

Improved Process for the Preparation of Naloxegol Oxalate, an Opiod Receptor Antagonist
por: Velugula, Siva Rama Kasibabu, et al.
Publicado: (2023)

Naloxegol hydrogen oxalate displaying a hydrogen-bonded layer structure
por: Gelbrich, Thomas, et al.
Publicado: (2018)

Can Naloxegol Therapy Improve Quality of Life in Patients with Advanced Cancer?
por: Ostan, Rita, et al.
Publicado: (2021)

Simulation and Prediction of the Drug‐Drug Interaction Potential of Naloxegol by Physiologically Based Pharmacokinetic Modeling
por: Zhou, D, et al.
Publicado: (2016)

Spotlight on naldemedine in the treatment of opioid-induced constipation in adult patients with chronic noncancer pain: design, development, and place in therapy
por: Stern, Emily K, et al.
Publicado: (2018)

Absorption, distribution, metabolism, and excretion of [(14)C]-labeled naloxegol in healthy subjects
por: Bui, Khanh, et al.
Publicado: (2015)

Lower and Upper Gastrointestinal Symptoms Differ Between Individuals With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation
por: Shah, Eric D, et al.
Publicado: (2018)

Effects of Naloxegol on Gastrointestinal Transit and Colonic Fecal Volume in Healthy Participants Receiving Oxycodone
por: Olesen, Anne E, et al.
Publicado: (2019)

Constipation in Elderly Patients with Noncancer Pain: Focus on Opioid-Induced Constipation
por: Chokhavatia, Sita, et al.
Publicado: (2016)

Methylnaltrexone in the treatment of opioid-induced constipation
por: Meerveld, Beverley Greenwood-Van, et al.
Publicado: (2008)

The changing landscape of opioid prescribing: long-acting and extended-release opioid class-wide Risk Evaluation and Mitigation Strategy
por: Gudin, Jeffrey A
Publicado: (2012)

Cost-Effectiveness of Vonoprazan- and Rifabutin-Based Regimens
por: Almenoff, June
Publicado: (2023)

The Spectrum of Constipation-Predominant Irritable Bowel Syndrome and Chronic Idiopathic Constipation: US Survey Assessing Symptoms, Care Seeking, and Disease Burden
por: Heidelbaugh, Joel J, et al.
Publicado: (2015)

Safety and efficacy of naldemedine in cancer patients with opioid-induced constipation: a pooled, subgroup analysis of two randomised controlled studies
por: Osaka, Iwao, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_mu977j48j40b58pf6soe5b5pfu